Therapeutic Impact of Etoposide against Ehrlich Solid Tumor Induced Cardiac Toxicity in Female Mice

Background and Objective: Breast cancer is one of the most common cause of cancer deaths among women worldwide. Etoposide is an important chemotherapeutic agent that is used to treat a wide spectrum of human cancers. It has been in clinical use for more than two decades and remains one of the most highly prescribed anticancer drugs in the world. The current study was conducted to compare the effect of Etoposide on cardiac function on none bearing tumor mice and bearing tumor mice.

Materials and Methods: A total of 40 albino females’ mice were separated into four groups (1st, control group; 2nd, Etoposide group; 3rd, EST group; 4th, EST treated with Etoposide group).

Results: EST induced changes in cardiac function and Electrolytes under study compared with control group. We found that LDH (lactate dehydrogenase), CK-MB (creatinine kinase) and CK (creatinine kinase), potassium ions (k+), chloride ions (Cl-), alkaline phosphatase (ALP) and aspartate aminotransferase (AST) were significantly increase in EST group compared with control group. In contrast, serum sodium ions had a significant decrease in EST group compared with control group. On the other hand, treatment with Etoposide for 14 days improved these changes in cardiac functions.

Conclusion: The present study confirmed the cardiac potential Etoposide. Further studies are warranted to explore its mode of action and safety for medicinal use in cancer therapy.